The active pharmaceutical ingredient in AZD2811 (AZD1152) has previously undergone clinical evaluation for diffuse large B-cell lymphoma (DLBCL), and the combination activity of aurora kinase B inhibitors and BH3 mimetics has been investigated in solid and hematologic malignancies (35). The gene discussed is AURKB; the disease is hematologic disorder.